C. Kilewo, K. Karlsson, A. Massawe, E. Lyamuya, A. Swai et al., Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study, J Acquir Immune Defic Syndr, vol.48, issue.3, pp.315-338, 1999.

N. Nagot, C. Kankasa, N. Meda, J. Hofmeyr, C. Nikodem et al.,

, Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174, BMC Infect Dis, vol.12, p.246, 2012.

, Children and HIV: Fact sheet | UNAIDS, Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach: 2010 Revision, 2010.

M. De-martino, P. A. Tovo, M. Balducci, L. Galli, C. Gabiano et al., Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry, JAMA. 12 juill, vol.284, issue.2, pp.190-197, 2000.

A. Violari, M. F. Cotton, D. M. Gibb, A. G. Babiker, J. Steyn et al., Early Antiretroviral Therapy and Mortality among HIV-Infected Infants, N Engl J Med, vol.359, issue.21, pp.2233-2277, 2008.

D. Sauvageot, M. Schaefer, D. Olson, M. Pujades-rodriguez, O. 'brien et al., Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age, Pediatrics. mai, vol.125, issue.5, pp.1039-1047, 2010.

S. Sollai, A. Noguera-julian, L. Galli, C. Fortuny, Á. Deyà et al., Strategies for the prevention of mother to child transmission in Western countries: an update, Pediatr Infect Dis J. mai, vol.34, issue.5, pp.14-30, 2015.

S. Nesheim, L. F. Harris, and M. Lampe, Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges, Curr Opin HIV AIDS. sept, vol.8, issue.5, pp.447-56, 2013.

, People living with HIV, HIV, antiretroviral therapy, new HIV infections, AIDS, tuberculosis, facts -UNAIDS_FactSheet_en.pdf [Internet

T. Goetghebuer, L. Chenadec, J. Haelterman, E. Galli, L. Dollfus et al., Shortand long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation, Clin Infect Dis Off Publ Infect Dis Soc Am. mars, vol.54, issue.6, pp.878-81, 2012.

M. Newell, H. Coovadia, M. Cortina-borja, N. Rollins, P. Gaillard et al., Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis, Lancet Lond Engl, vol.364, issue.9441, pp.1236-1279, 2004.

T. E. Taha, S. M. Graham, N. I. Kumwenda, R. L. Broadhead, D. R. Hoover et al., Morbidity among human immunodeficiency virus-1-infected and -uninfected African children, Pediatrics. déc, vol.106, issue.6, p.77, 2000.

M. F. Cotton, A. Violari, K. Otwombe, R. Panchia, E. Dobbels et al., Early timelimited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial, Lancet Lond Engl, vol.382, issue.9904, pp.1555-63, 2013.

M. J. Mayaux, M. Burgard, J. P. Teglas, J. Cottalorda, A. Krivine et al., Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group, JAMA J Am Med Assoc. 28 févr, vol.275, issue.8, pp.606-616, 1996.

M. Davies, S. Phiri, R. Wood, M. Wellington, V. Cox et al., Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration, PLoS ONE. 19 juill, vol.8, issue.9, p.21840, 2011.

S. E. Purchase, D. J. Van-der-linden, and N. H. Mckerrow, Feasibility and effectiveness of early initiation of combination antiretroviral therapy in HIV-infected infants in a government clinic of Kwazulu-Natal, South Africa, J Trop Pediatr. avr, vol.58, issue.2, pp.114-123, 2012.

V. J. Tukei, M. Murungi, A. R. Asiimwe, D. Migisha, A. Maganda et al., immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda. BMC Pediatr, vol.13, p.42, 2013.

B. Eley, M. Davies, P. Apolles, C. Cowburn, H. Buys et al., Antiretroviral treatment for children, South Afr Med J Suid-Afr Tydskr Vir Geneeskd. sept, vol.96, issue.9, pp.988-93, 2006.

E. Chiappini, L. Galli, P. Tovo, C. Gabiano, C. Lisi et al., Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy, BMC Infect Dis. 26 août, vol.9, issue.1, p.1, 2009.

, OMS | Lignes directrices unifiées sur l'utilisation des antirétroviraux pour le traitement et la prévention de l'infection à VIH

, OMS | Traiter toutes les personnes vivant avec le VIH

D. Sur,

C. A. Sabin, C. J. Smith, A. Monforte, M. Battegay, and C. Gabiano, Response to combination antiretroviral therapy: variation by age, AIDS Lond Engl. 31 juill, vol.22, issue.12, pp.1463-73, 2008.

B. O. Taiwo and R. L. Murphy, Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa, Cytometry B Clin Cytom, vol.74, issue.1, pp.11-18, 2008.

B. Janssens, B. Raleigh, S. Soeung, K. Akao, V. Te et al., Effectiveness of Highly Active Antiretroviral Therapy in HIV-Positive Children: Evaluation at 12 Months in a Routine Program in Cambodia, Pediatrics, vol.120, issue.5, pp.1134-1174, 2007.
URL : https://hal.archives-ouvertes.fr/pasteur-00599045

E. George, F. Noël, G. Bois, R. Cassagnol, L. Estavien et al., Antiretroviral Therapy for HIV-1-Infected Children in Haiti, J Infect Dis. 15 mai, vol.195, issue.10, pp.1411-1419, 2007.

D. P. O'brien, D. Sauvageot, R. Zachariah, and P. Humblet, Medecins Sans Frontieres. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy, AIDS Lond Engl, vol.20, issue.15, pp.1955-60, 2006.

R. E. Barth, H. A. Tempelman, E. Smelt, A. Wensing, A. I. Hoepelman et al., Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment, Pediatr Infect Dis J. janv, vol.30, issue.1, pp.52-58, 2011.

A. Prendergast, W. Mphatswe, T. , G. Rakgotho, M. Pillay et al., Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants, AIDS Lond Engl. 11 juill, vol.22, issue.11, pp.1333-1376, 2008.

A. Kekitiinwa, K. J. Lee, A. S. Walker, A. Maganda, K. Doerholt et al., Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIVinfected children in Kampala, Uganda, and the United Kingdom/Ireland, J Acquir Immune Defic Syndr, vol.49, issue.4, pp.384-92, 1999.

B. C. Zanoni, T. Phungula, H. M. Zanoni, H. France, E. F. Cook et al., Predictors of Poor CD4 and Weight Recovery in HIV-Infected Children Initiating ART in South Africa, PLOS ONE. 16 mars, vol.7, issue.3, p.33611, 2012.

C. Ndondoki, F. Dicko, A. Coffie, P. , K. Eboua et al., Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa, Disponible sur, vol.17, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01108201

A. L. Ciaranello, Y. Chang, A. V. Margulis, A. Bernstein, I. V. Bassett et al., Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 déc, vol.49, issue.12, pp.1915-1942, 2009.

, The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Response to early antiretroviral therapy in HIV-1 infected infants in Europe, vol.25, pp.2279-87, 1996.

A. Van-rossum, P. Fraaij, and R. De-groot, Efficacy of highly active antiretroviral therapy in HIV-1 infected children, Lancet Infect Dis. févr, vol.2, issue.2, pp.93-102, 2002.

P. Fraaij, G. Verweel, A. Van-rossum, E. G. Van-lochem, M. Schutten et al., Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 févr, vol.40, issue.4, pp.604-612, 2005.

J. Aboulker, A. Babiker, M. L. Chaix, A. Compagnucci, J. Darbyshire et al., Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome, AIDS Lond Engl. 23 janv, vol.18, issue.2, pp.237-282, 2004.

A. S. Walker, K. Doerholt, M. Sharland, and D. M. Gibb, Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study, AIDS Lond Engl. 24 sept, vol.18, issue.14, pp.1915-1939, 2004.

, OMS | Lignes directrices unifiées sur l'utilisation des antirétroviraux pour le traitement et la prévention de l'infection à VIH

P. L. Havens and D. M. Gibb, Increasing antiretroviral drug access for children with HIV infection, American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health, vol.119, issue.4, pp.838-883, 2007.

J. D. Church, S. B. Omer, L. A. Guay, W. Huang, J. Lidstrom et al., Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite receiving single dose (SD) nevirapine (NVP) vs. SD NVP plus daily NVP up to 6-weeks of age to prevent HIV vertical transmission, J Infect Dis, vol.198, issue.7, pp.1075-82, 2008.

M. A. Chesney, The elusive gold standard. Future perspectives for HIV adherence assessment and intervention, J Acquir Immune Defic Syndr, vol.43, issue.1, pp.149-155, 1999.

J. E. Haberer, J. Kiwanuka, D. Nansera, K. Ragland, C. Mellins et al., Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children, PloS One, vol.7, issue.5, p.36737, 2012.

D. M. Gibb, R. L. Goodall, V. Giacomet, L. Mcgee, A. Compagnucci et al., Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial, Pediatr Infect Dis J. janv, vol.22, issue.1, pp.56-62, 2003.

A. D. Müller, H. B. Jaspan, L. Myer, A. L. Hunter, G. Harling et al., Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting, AIDS Behav. févr, vol.15, issue.2, pp.422-453, 2011.

A. D. Müller, S. Bode, L. Myer, P. Roux, V. Steinbüchel et al., Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa, Pediatr Infect Dis J. mars, vol.27, issue.3, pp.257-62, 2008.

, Know your epidemic, Disponible sur

, MICS4 Preliminary Findings -Cameroon 2014 MICS KFR_French

D. Sur,

. Unaids_globalplancountryfactsheet_cameroon_en and . Pdf,

D. Sur,

C. National-de-lutte-contre-le, V. Sida-(cnls), and M. Cameroun, Rapport annuel des activités des IST/ SIDA, 2012.

M. C. Tejiokem, J. Warszawski, A. Ndongo, F. , T. Ndiang et al., Feasibility of Routinely Offering Early Combined Antiretroviral Therapy to HIVinfected Infants in a Resource-limited Country: The ANRS-PediaCAM Study in Cameroon, Pediatr Infect Dis J. oct, vol.34, issue.10, pp.248-253, 2015.

P. M. Musoke, P. Mudiope, L. N. Barlow-mosha, P. Ajuna, D. Bagenda et al., Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study, BMC Pediatr, vol.10, issue.1, p.56, 2010.

A. F. Schoffelen, A. Wensing, H. A. Tempelman, S. Geelen, A. Hoepelman et al., Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa. Sluis-Cremer N, éditeur, PLoS ONE. 11 mars, vol.8, issue.3, p.58526, 2013.

K. L. Fielding, S. Charalambous, A. L. Stenson, L. F. Pemba, D. J. Martin et al., Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study, BMC Infect Dis, vol.8, issue.1, p.93, 2008.

J. M. Satagopan, L. Ben-porat, M. Berwick, M. Robson, D. Kutler et al., A note on competing risks in survival data analysis, Br J Cancer, vol.91, issue.7, pp.1229-1264, 2004.

, An Introduction to Survival Analysis Using Stata, Second Edition, vol.398, 2008.

A. Ndongo, F. Warszawski, J. Texier, G. Penda, I. et al., Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?, BMC Pediatr, vol.15, issue.1, p.132, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01264484

T. Puthanakit, L. Aurpibul, P. Oberdorfer, N. Akarathum, S. Kanjananit et al., Hospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral Therapy, Clin Infect Dis. 15 févr, vol.44, issue.4, pp.599-604, 2007.

J. H. Dijk, . Van, C. G. Sutcliffe, B. Munsanje, P. Sinywimaanzi et al., HIV-Infected Children in Rural Zambia Achieve Good Immunologic and Virologic Outcomes Two Years after Initiating Antiretroviral Therapy, PLOS ONE. avr, vol.6, issue.4, p.19006, 2011.

R. Weigel, J. Estill, M. Egger, A. D. Harries, S. Makombe et al., Mortality and loss to follow-up in the first year of ART: Malawi national ART programme, AIDS Lond Engl. 28 janv, vol.26, issue.3, pp.365-73, 2012.

F. Rouet, P. Fassinou, A. Inwoley, M. Anaky, A. Kouakoussui et al., Longterm survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens, AIDS Lond Engl, vol.20, issue.18, pp.2315-2324, 2006.

J. D. Goldman, R. A. Cantrell, L. B. Mulenga, B. C. Tambatamba, S. E. Reid et al., Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy, AIDS Res Hum Retroviruses. août, vol.24, issue.8, pp.1031-1036, 2008.

H. Liu, C. E. Golin, L. G. Miller, R. D. Hays, C. K. Beck et al., A comparison study of multiple measures of adherence to HIV protease inhibitors, Ann Intern Med. 15 mai, vol.134, issue.10, pp.968-77, 2001.

G. J. Wagner and J. G. Rabkin, Measuring medication adherence: are missed doses reported more accurately then perfect adherence?, AIDS Care. août, vol.12, issue.4, pp.405-413, 2000.

J. Farley, S. Hines, A. Musk, S. Ferrus, and V. Tepper, Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, J Acquir Immune Defic Syndr, vol.33, issue.2, pp.211-219, 1999.

L. Ahoua, G. Guenther, C. Rouzioux, L. Pinoges, P. Anguzu et al., Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1-and 2-year outcomes in rural Uganda, BMC Pediatr, vol.11, p.67, 2011.

F. Zhang, J. E. Haberer, Y. Zhao, Z. Dou, H. Zhao et al., Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes, J Acquir Immune Defic Syndr, vol.46, issue.5, pp.594-602, 1999.

V. Pillay, M. Davies, S. King, and B. Eley, Short-term treatment outcomes of children starting antiretroviral therapy in the intensive care unit, general medical wards and outpatient HIV clinics at Red Cross War Memorial Children's Hospital, Cape Town, South Africa: A retrospective cohort study, South Afr Med J Suid-Afr Tydskr Vir Geneeskd. mars, vol.105, issue.3, pp.220-227, 2015.

P. Palumbo, J. C. Lindsey, M. D. Hughes, M. F. Cotton, R. Bobat et al., Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure, N Engl J Med, vol.363, issue.16, pp.1510-1530, 2010.

A. Violari, J. C. Lindsey, M. D. Hughes, H. A. Mujuru, L. Barlow-mosha et al., Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children, N Engl J Med. juin, vol.366, issue.25, pp.2380-2389, 2012.

A. J. Prendergast, M. Penazzato, M. Cotton, P. Musoke, V. Mulenga et al., First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial, Lancet Infect Dis. avr, vol.9, issue.7, pp.273-83, 2011.

P. Isaakidis, M. Raguenaud, V. Te, C. S. Tray, K. Akao et al., High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia, J Int AIDS Soc, vol.13, issue.1, p.11, 2010.

T. D. Ruel, M. R. Kamya, P. Li, W. Pasutti, E. D. Charlebois et al., Early Virologic Failure and the Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Ugandan Children, JAIDS J Acquir Immune Defic Syndr. janv, vol.56, issue.1, pp.44-50, 2011.

M. Penazzato and C. Giaquinto, Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children, Drugs, vol.12, issue.16, pp.2131-2180, 2011.

A. Violari, M. F. Cotton, D. M. Gibb, A. G. Babiker, J. Steyn et al., Early antiretroviral therapy and mortality among HIV-infected infants, N Engl J Med, vol.359, issue.21, pp.2233-2277, 2008.

, WHO | Progress report 2011: Global HIV/AIDS response

M. Porter, M. Davies, M. K. Mapani, H. Rabie, S. Phiri et al., Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, J Acquir Immune Defic Syndr, vol.69, issue.5, pp.593-601, 1999.

J. H. Van-dijk, C. G. Sutcliffe, B. Munsanje, P. Sinywimaanzi, F. Hamangaba et al., HIV-Infected Children in Rural Zambia Achieve Good Immunologic and Virologic Outcomes Two Years after Initiating Antiretroviral Therapy. Myer L, éditeur, PLoS ONE. 28 avr, vol.6, issue.4, p.19006, 2011.

T. Goetghebuer, L. Chenadec, J. Haelterman, E. Galli, L. Dollfus et al., Shortand Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation, Clin Infect Dis. 15 mars, vol.54, issue.6, pp.878-81, 2012.

K. H. Ásbjörnsdóttir, J. P. Hughes, D. Wamalwa, A. Langat, J. A. Slyker et al., Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children, AIDS Lond Engl, vol.30, issue.18, pp.2835-2878, 2016.

A. L. Moore, O. Kirk, A. M. Johnson, C. Katlama, A. Blaxhult et al., Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited, J Acquir Immune Defic Syndr, vol.32, issue.4, pp.452-61, 1999.

P. Palumbo, H. Wu, E. Chadwick, P. Ruan, K. Luzuriaga et al., Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection, J Infect Dis. 1 juill, vol.196, issue.1, pp.23-32, 2007.

A. Violari, J. C. Lindsey, M. D. Hughes, H. A. Mujuru, L. Barlow-mosha et al., Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children, N Engl J Med. 21 juin, vol.366, issue.25, pp.2380-2389, 2012.

U. Md and . Douala,

H. Laquintinie, POB 4035 Douala, Cameroon; e-mail: 12 idapenda@yahoo.fr

P. Md and C. Pasteur-du-cameroun, Service d'Epidémiologie et de Santé Publique, POB, vol.1274, p.14

C. Md, Hospitalier d'Essos, POB 5777 Yaounde, Cameroon; e-mail: ndiangsuzie@yahoo.fr

C. Md, Mère et Enfant de la Fondation Chantal Biya, POB 1936 Yaounde, Cameroon; e-mail: 17 jeanndongo@yahoo.fr

, POB, 1936.

M. Msc and U. Yaoundé,

, Centre Pasteur du Cameroun, Service d'Epidémiologie et de 21

S. Publique, POB 1274 Yaounde, Cameroon; e-mail: scl.ledoux@gmail.com

C. Kilewo, K. Karlsson, A. Massawe, E. Lyamuya, A. Swai et al., Prevention of 2 mother-to-child transmission of HIV-1 through breast-feeding by treating infants 3 prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study

, Acquir Immune Defic Syndr 1999. 1 juill, vol.48, pp.315-338, 2008.

N. Nagot, C. Kankasa, N. Meda, J. Hofmeyr, C. Nikodem et al.,

, Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 7 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. BMC 8 Infect Dis, vol.12, p.246, 2012.

, Children and HIV: Fact sheet | UNAIDS, Antiretroviral Therapy for HIV Infection in Infants and Children: Towards 10 Universal Access: Recommendations for a Public Health Approach, p.11, 2010.

M. De-martino, P. A. Tovo, M. Balducci, L. Galli, C. Gabiano et al., Reduction in 19 mortality with availability of antiretroviral therapy for children with perinatal HIV-1 20 infection. Italian Register for HIV Infection in Children and the Italian National AIDS 21 Registry, JAMA. 12 juill, vol.284, issue.2, pp.190-197, 2000.

T. E. Taha, S. M. Graham, N. I. Kumwenda, R. L. Broadhead, D. R. Hoover et al.,

, Morbidity among human immunodeficiency virus-1-infected and -uninfected African 7 children, Pediatrics. déc, vol.106, issue.6, p.77, 2000.

M. F. Cotton, A. Violari, K. Otwombe, R. Panchia, E. Dobbels et al., Early time-9 limited antiretroviral therapy versus deferred therapy in South African infants infected 10 with HIV: results from the children with HIV early antiretroviral (CHER) randomised 11 trial, Lancet Lond Engl, vol.382, issue.9904, pp.1555-63, 2013.

M. J. Mayaux, M. Burgard, J. P. Teglas, J. Cottalorda, A. Krivine et al., Neonatal 13 characteristics in rapidly progressive perinatally acquired HIV-1 disease, The French, p.14

, Pediatric HIV Infection Study Group, JAMA J Am Med Assoc. 28 févr, vol.15, issue.8, pp.606-616, 1996.

M. Davies, S. Phiri, R. Wood, M. Wellington, V. Cox et al., Temporal 17 Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in 18

;. Southern-africa, M. C. Tejiokem, F. A. Penda, I. C. Guemkam, G. et al., The IeDEA-SA Collaboration. PLoS ONE [Internet, vol.8, 2013.

B. O. Taiwo and R. L. Murphy, Clinical applications and availability of CD4+ T cell count 1 testing in sub-Saharan Africa, Cytometry B Clin Cytom, vol.74, issue.1, pp.11-18, 2008.

B. Janssens, B. Raleigh, S. Soeung, K. Akao, V. Te et al., , p.3

, Active Antiretroviral Therapy in HIV-Positive Children: Evaluation at 12 Months in a 4

, Routine Program in Cambodia, Pediatrics, vol.120, issue.5, pp.1134-1174, 2007.

E. George, F. Noël, G. Bois, R. Cassagnol, L. Estavien et al., Antiretroviral 6 Therapy for HIV-1-Infected Children in Haiti, J Infect Dis, vol.15, issue.7, pp.1411-1419, 2007.

D. P. O'brien, D. Sauvageot, R. Zachariah, and P. Humblet, Medecins Sans Frontieres. In 9 resource-limited settings good early outcomes can be achieved in children using adult 10 fixed-dose combination antiretroviral therapy, AIDS Lond Engl, vol.20, issue.15, pp.1955-60, 2006.

R. E. Barth, H. A. Tempelman, E. Smelt, A. Wensing, A. I. Hoepelman et al., Long-13 term outcome of children receiving antiretroviral treatment in rural South Africa: 14 substantial virologic failure on first-line treatment, Pediatr Infect Dis J. janv, vol.15, issue.1, pp.52-58, 2011.

A. Prendergast, W. Mphatswe, T. , G. Rakgotho, M. Pillay et al., Early virological suppression with three-class antiretroviral therapy in HIV-18 infected African infants, AIDS Lond Engl. 11 juill, vol.22, issue.11, pp.1333-1376, 2008.

A. Kekitiinwa, K. J. Lee, A. S. Walker, A. Maganda, K. Doerholt et al.,

, Differences in factors associated with initial growth, CD4, and viral load responses to 21 ART in HIV-infected children in Kampala, p.22

, Acquir Immune Defic Syndr 1999. 1 déc, vol.49, pp.384-92, 2008.

B. C. Zanoni, T. Phungula, H. M. Zanoni, H. France, E. F. Cook et al., Predictors, p.24

, Poor CD4 and Weight Recovery in HIV-Infected Children Initiating ART in South 25

. Africa, C. Plos-one-;-ndondoki, F. Dicko, A. Coffie, P. et al., 16 mars, vol.7, p.27, 2012.

K. Kouadio, Antiretroviral treatment response of HIV-infected children after 28 prevention of mother-to-child transmission in West Africa, J Int AIDS Soc, vol.17, issue.1

A. L. Ciaranello, Y. Chang, A. V. Margulis, A. Bernstein, I. V. Bassett et al.,

, Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a 33 systematic review and meta-analysis, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 34 déc, vol.49, issue.12, pp.1915-1942, 2009.

, The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study 36 group in EuroCoord. Response to early antiretroviral therapy in HIV-1 infected infants 37 in Europe, AIDS Lond Engl, vol.25, issue.18, pp.2279-87, 1996.

A. Van-rossum, P. Fraaij, and R. De-groot, Efficacy of highly active antiretroviral 39 therapy in HIV-1 infected children, Lancet Infect Dis. févr, vol.2, issue.2, pp.93-102, 2002.

P. Fraaij, G. Verweel, A. Van-rossum, E. G. Van-lochem, M. Schutten et al.,

. Cmr, Sustained viral suppression and immune recovery in HIV type 1-infected 2 children after 4 years of highly active antiretroviral therapy, Clin Infect Dis Off Publ, vol.3

, Infect Dis Soc Am. 15 févr, vol.40, issue.4, pp.604-612, 2005.

J. Aboulker, A. Babiker, M. L. Chaix, A. Compagnucci, J. Darbyshire et al.,

, Highly active antiretroviral therapy started in infants under 3 months of age: 72-week 6 follow-up for CD4 cell count, viral load and drug resistance outcome, AIDS Lond, vol.7

, Engl. 23 janv, vol.18, issue.2, pp.237-282, 2004.

A. S. Walker, K. Doerholt, M. Sharland, and D. M. Gibb, CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies 10 with age: the UK and Ireland Collaborative HIV Paediatric Study, Collaborative HIV Paediatric Study, vol.9, issue.14, pp.1915-1939, 2004.

, Section on 16 International Child Health, Havens PL, Gibb DM. Increasing antiretroviral drug access 17 for children with HIV infection, OMS | Lignes directrices unifiées sur l'utilisation des antirétroviraux pour le traitement 13 et la prévention de l'infection à VIH, vol.119, pp.838-883, 2007.

J. D. Church, S. B. Omer, L. A. Guay, W. Huang, J. Lidstrom et al., Analysis of 19 nevirapine (NVP) resistance in Ugandan infants who were HIV-infected despite 20 receiving single dose (SD) nevirapine (NVP) vs. SD NVP plus daily NVP up to 6-21 weeks of age to prevent HIV vertical transmission, J Infect Dis, vol.198, issue.7, pp.1075-82, 2008.

F. Fitzgerald, M. Penazzato, and D. Gibb, Development of Antiretroviral Resistance in 24

, Children With HIV in Low-and Middle-Income Countries, vol.25, pp.85-92, 2013.

P. Jittamala, T. Puthanakit, S. Chaiinseeard, and V. Sirisanthana, Predictors of virologic 3 failure and genotypic resistance mutation patterns in thai children receiving non-4 nucleoside reverse transcriptase inhibitor-based antiretroviral therapy, Pediatr Infect, vol.5

, Dis J. sept, vol.28, issue.9, pp.826-856, 2009.

S. D. Emmett, C. K. Cunningham, B. T. Mmbaga, G. D. Kinabo, W. Schimana et al.,

, Predicting virologic failure among HIV-1-infected children receiving antiretroviral 8 therapy in Tanzania: a cross-sectional study, J Acquir Immune Defic Syndr, vol.9, issue.4, pp.368-75, 1999.

M. , N. , H. , G. , K. et al., Reducing CD4 monitoring in children on 11 antiretroviral therapy with virologic suppression, Pediatr Infect Dis J. 1 janv, vol.12, pp.1361-1365, 2015.

M. C. Hosseinipour, J. Van-oosterhout, R. Weigel, S. Phiri, D. Kamwendo et al., The public health approach to identify antiretroviral therapy failure: high-level 15 nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line 16 antiretroviral therapy, AIDS Lond Engl. 1 juin, vol.23, issue.9, pp.1127-1161, 2009.

C. Bolton-moore, M. Mubiana-mbewe, R. A. Cantrell, N. Chintu, E. M. Stringer et al., Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy 19 at primary health care facilities in Zambia, JAMA, vol.298, issue.16, pp.1888-99, 2007.

M. A. Chesney, Future perspectives for HIV adherence 21 assessment and intervention, J Acquir Immune Defic Syndr, vol.43, issue.1, 1999.

. Key%20findings/cameroon%202014%20mics%20kfr_french, , vol.29

D. Sur,

C. National-de-lutte-contre-le, V. Sida-(cnls), and M. Cameroun,

, Rapport annuel des activités des IST/ SIDA, 2012.

M. C. Tejiokem, J. Warszawski, A. Ndongo, F. , T. Ndiang et al., Feasibility of Routinely Offering Early Combined Antiretroviral Therapy, p.12

, HIV-infected Infants in a Resource-limited Country: The ANRS-PediaCAM Study in 13

. Cameroon, Pediatr Infect Dis J. oct, vol.34, issue.10, pp.248-253, 2015.

P. M. Musoke, P. Mudiope, L. N. Barlow-mosha, P. Ajuna, D. Bagenda et al.,

A. F. Schoffelen, A. Wensing, H. A. Tempelman, S. Geelen, and A. Hoepelman, Growth, immune and viral responses in HIV infected African children receiving highly 16 active antiretroviral therapy: a prospective cohort study, vol.10, pp.56-73, 2010.

, Virological Failure in HIV-Infected Patients in Rural South Africa. Sluis-Cremer N, 20 éditeur, PLoS ONE. 11 mars, vol.8, issue.3, p.58526, 2013.

K. L. Fielding, S. Charalambous, A. L. Stenson, L. F. Pemba, D. J. Martin et al., Risk 22 factors for poor virological outcome at 12 months in a workplace-based antiretroviral 23 therapy programme in South Africa: A cohort study, BMC Infect Dis, vol.8, issue.1, pp.1229-1264, 2004.

, An Introduction to Survival Analysis Using Stata, Second Edition, 2008.

A. Ndongo, F. Warszawski, J. Texier, G. Penda, I. et al., Could caregiver reporting adherence help detect virological failure in Cameroonian 30 early treated HIV-infected infants?, BMC Pediatr, vol.15, issue.1, p.132, 2015.

T. Puthanakit, L. Aurpibul, P. Oberdorfer, N. Akarathum, S. Kanjananit et al.,

, Hospitalization and Mortality among HIV-Infected Children after Receiving Highly 33

, Active Antiretroviral Therapy. Clin Infect Dis. 15 févr, vol.44, issue.4, pp.599-604, 2007.

J. H. Dijk, . Van, C. G. Sutcliffe, B. Munsanje, P. Sinywimaanzi et al., HIV-Infected Children in Rural Zambia Achieve Good Immunologic and Virologic 36

, Outcomes Two Years after Initiating Antiretroviral Therapy, PLOS ONE. avr, vol.37, issue.4, p.19006, 2011.

R. Weigel, J. Estill, M. Egger, A. D. Harries, S. Makombe et al., Mortality and 1 loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 2 Lond Engl, 28 janv, vol.26, issue.3, pp.365-73, 2012.

F. Rouet, P. Fassinou, A. Inwoley, M. Anaky, A. Kouakoussui et al., Long-4 term survival and immuno-virological response of African HIV-1-infected children to 5 highly active antiretroviral therapy regimens, AIDS Lond Engl, vol.28, issue.18, pp.2315-2324, 2006.

J. D. Goldman, R. A. Cantrell, L. B. Mulenga, B. C. Tambatamba, S. E. Reid et al.,

, Simple adherence assessments to predict virologic failure among HIV-infected adults 9 with discordant immunologic and clinical responses to antiretroviral therapy, AIDS Res, vol.10

, Hum Retroviruses. août, vol.24, issue.8, pp.1031-1036, 2008.

H. Liu, C. E. Golin, L. G. Miller, R. D. Hays, C. K. Beck et al., A comparison 12 study of multiple measures of adherence to HIV protease inhibitors, Ann Intern Med. 13 15 mai, vol.134, issue.10, pp.968-77, 2001.

G. J. Wagner and J. G. Rabkin, Measuring medication adherence: are missed doses reported 15 more accurately then perfect adherence?, AIDS Care. août, vol.12, issue.4, pp.405-413, 2000.

J. Farley, S. Hines, A. Musk, S. Ferrus, and V. Tepper, Assessment of adherence to antiviral 17 therapy in HIV-infected children using the Medication Event Monitoring System, 18 pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, J, vol.19

, Acquir Immune Defic Syndr 1999. 1 juin, vol.33, issue.2, pp.211-219, 2003.

L. Ahoua, G. Guenther, C. Rouzioux, L. Pinoges, P. Anguzu et al.,

, Immunovirological response to combined antiretroviral therapy and drug resistance 22 patterns in children: 1-and 2-year outcomes in rural Uganda, BMC Pediatr, vol.23, p.67, 2011.

F. Zhang, J. E. Haberer, Y. Zhao, Z. Dou, H. Zhao et al., Chinese pediatric highly 25 active antiretroviral therapy observational cohort: a 1-year analysis of clinical, 26 immunologic, and virologic outcomes, J Acquir Immune Defic Syndr, vol.27, issue.5, pp.594-602, 1999.

V. Pillay, M. Davies, S. King, and B. Eley, Short-term treatment outcomes of children 29 starting antiretroviral therapy in the intensive care unit, general medical wards and 30 outpatient HIV clinics at Red Cross War Memorial Children's Hospital, p.31

, South Africa: A retrospective cohort study, South Afr Med J Suid-Afr Tydskr Vir, vol.32

, Geneeskd. mars, vol.105, issue.3, pp.220-227, 2015.

P. Palumbo, J. C. Lindsey, M. D. Hughes, M. F. Cotton, R. Bobat et al.,

, Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure, N Engl J, vol.35

. Med, , vol.363, pp.1510-1530, 2010.

A. Violari, J. C. Lindsey, M. D. Hughes, H. A. Mujuru, L. Barlow-mosha et al.,

, Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children, N Engl J, vol.38

, Med. juin, vol.366, issue.25, pp.2380-2389, 2012.

A. J. Prendergast, M. Penazzato, M. Cotton, P. Musoke, V. Mulenga et al., 40 Treatment of Young Children with HIV Infection: Using Evidence to Inform 41

. Policymakers, PENPACT-1 (PENTA 9/PACTG 390) Study Team, PLoS Med, vol.9, issue.7, 2012.

A. Compagnucci, S. Fiscus, and C. Giaquinto, First-line antiretroviral therapy with a 4 protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at 5 higher versus low viral load in HIV-infected children: an open-label, randomised phase 6 2/3 trial, Lancet Infect Dis. avr, vol.11, issue.4, pp.273-83, 2011.

P. Isaakidis, M. Raguenaud, V. Te, C. S. Tray, K. Akao et al., High survival 8 and treatment success sustained after two and three years of first-line ART for children 9 in Cambodia, J Int AIDS Soc, vol.13, issue.1, p.11, 2010.

T. D. Ruel, M. R. Kamya, P. Li, W. Pasutti, E. D. Charlebois et al., Early Virologic 11 Failure and the Development of Antiretroviral Drug Resistance Mutations

, J Acquir Immune Defic Syndr. janv, vol.13, issue.1, pp.44-50, 2011.

M. Penazzato and C. Giaquinto, Role of non-nucleoside reverse transcriptase inhibitors in 15 treating HIV-infected children, Drugs, vol.12, issue.16, pp.2131-2180, 2011.

A. Violari, M. F. Cotton, D. M. Gibb, A. G. Babiker, J. Steyn et al., Early 17 antiretroviral therapy and mortality among HIV-infected infants, N Engl J Med, vol.359, issue.21, pp.2233-2277, 2008.

, WHO | Progress report 2011: Global HIV/AIDS response, vol.13

D. Sur,

M. Porter, M. Davies, M. K. Mapani, H. Rabie, S. Phiri et al., , p.22

, Infants Starting Antiretroviral Therapy in Southern Africa, p.23, 2004.

, Immune Defic Syndr, 15 août, vol.69, issue.5, pp.593-601, 1999.

M. C. Tejiokem, J. Warszawski, A. Ndongo, F. , T. Ndiang et al., Owona 25 F, et al. Feasibility of Routinely Offering Early Combined Antiretroviral Therapy to 26

, HIV-infected Infants in a Resource-limited Country: The ANRS-PediaCAM Study, p.27

. Cameroon, Pediatr Infect Dis J. oct, vol.34, issue.10, pp.248-253, 2015.

A. S. Walker, K. Doerholt, M. Sharland, and D. M. Gibb, Collaborative HIV Paediatric Study 29 (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies 30 with age: the UK and Ireland Collaborative HIV Paediatric Study, AIDS Lond Engl. 24 31 sept, vol.18, issue.14, pp.1915-1939, 2004.

J. H. Van-dijk, C. G. Sutcliffe, B. Munsanje, P. Sinywimaanzi, F. Hamangaba et al., HIV-Infected Children in Rural Zambia Achieve Good Immunologic and Virologic 34

, Outcomes Two Years after Initiating Antiretroviral Therapy. Myer L, éditeur. PLoS 35 ONE. 28 avr, vol.6, p.19006, 2011.

T. Goetghebuer, L. Chenadec, J. Haelterman, E. Galli, L. Dollfus et al.,

, Short-and Long-term Immunological and Virological Outcome in HIV-Infected Infants 38

, According to the Age at Antiretroviral Treatment Initiation, Clin Infect Dis. 15 mars, vol.39, issue.6, pp.878-81, 2012.

K. H. Ásbjörnsdóttir, J. P. Hughes, D. Wamalwa, A. Langat, J. A. Slyker et al.,

, Differences in virologic and immunologic response to antiretroviral therapy among 2 HIV-1-infected infants and children, AIDS Lond Engl, vol.30, issue.18, pp.2835-2878, 2016.

A. L. Moore, O. Kirk, A. M. Johnson, C. Katlama, A. Blaxhult et al., , p.4

, immunologic, and clinical response to highly active antiretroviral therapy: the gender 5 issue revisited, J Acquir Immune Defic Syndr, vol.32, issue.4, pp.452-61, 1999.

P. Palumbo, H. Wu, E. Chadwick, P. Ruan, K. Luzuriaga et al., Virologic 7 response to potent antiretroviral therapy and modeling of HIV dynamics in early 8 pediatric infection, J Infect Dis. 1 juill, vol.196, issue.1, pp.23-32, 2007.

A. Violari, J. C. Lindsey, M. D. Hughes, H. A. Mujuru, L. Barlow-mosha et al.,

, Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children, N Engl J Med. 11 21 juin, vol.366, issue.25, pp.2380-2389, 2012.

, PENPACT-1 (PENTA 9/PACTG 390) Study Team, vol.136, p.13

A. Compagnucci, S. Fiscus, and C. Giaquinto, First-line antiretroviral therapy with a 14 protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at 15 higher versus low viral load in HIV-infected children: an open-label, randomised phase 16 2/3 trial, Lancet Infect Dis. avr, vol.11, issue.4, pp.273-83, 2011.

K. Sigaloff, J. Calis, S. P. Geelen, M. Van-vugt, and T. De-wit, HIV-1-resistance-18 associated mutations after failure of first-line antiretroviral treatment among children in 19 resource-poor regions: a systematic review, Lancet Infect Dis, vol.11, issue.10, pp.769-79, 2011.